High Vista Strategies LLC Prothena Corp Public LTD CO Transaction History

High Vista Strategies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $131,919 - $196,903	2,789 Added 43.54%	9,195 $443,000
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $394,091 - $641,765	-8,166 Reduced 56.04%	6,406 $437,000
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $758,472 - $947,180	14,572 New	14,572 $877,000
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $294,421 - $517,860	-12,953 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $457,833 - $744,452	-15,125 Reduced 53.87%	12,953 $474,000
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $1.18 Million - $2.06 Million	28,078 New	28,078 $1.39 Million
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $449,469 - $619,131	-44,414 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$9.93 - $13.47 $441,031 - $598,256	44,414 New	44,414 $444,000

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.